TR201806912T4 - Tek zincirli traıl-reseptörü agonist proteinleri. - Google Patents

Tek zincirli traıl-reseptörü agonist proteinleri. Download PDF

Info

Publication number
TR201806912T4
TR201806912T4 TR2018/06912T TR201806912T TR201806912T4 TR 201806912 T4 TR201806912 T4 TR 201806912T4 TR 2018/06912 T TR2018/06912 T TR 2018/06912T TR 201806912 T TR201806912 T TR 201806912T TR 201806912 T4 TR201806912 T4 TR 201806912T4
Authority
TR
Turkey
Prior art keywords
trail
receptor agonist
sek
protein
region
Prior art date
Application number
TR2018/06912T
Other languages
English (en)
Turkish (tr)
Inventor
Hill Oliver
Gieffers Christian
Thiemann Meinolf
Fritz Buchanan G
Darren Phillips C
Susan Lappe E
Original Assignee
Abbvie Inc
Apogenix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Apogenix Ag filed Critical Abbvie Inc
Publication of TR201806912T4 publication Critical patent/TR201806912T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
TR2018/06912T 2014-04-23 2015-04-23 Tek zincirli traıl-reseptörü agonist proteinleri. TR201806912T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
TR201806912T4 true TR201806912T4 (tr) 2018-06-21

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/06912T TR201806912T4 (tr) 2014-04-23 2015-04-23 Tek zincirli traıl-reseptörü agonist proteinleri.

Country Status (38)

Country Link
US (5) US9908927B2 (enExample)
EP (2) EP3366699A1 (enExample)
JP (2) JP6523331B2 (enExample)
KR (2) KR102079919B1 (enExample)
CN (2) CN106459221B (enExample)
AR (1) AR100168A1 (enExample)
AU (3) AU2015249649B2 (enExample)
BR (1) BR112016024515B1 (enExample)
CA (2) CA3184067A1 (enExample)
CL (1) CL2016002683A1 (enExample)
CR (1) CR20160516A (enExample)
CY (1) CY1120281T1 (enExample)
DK (1) DK3134430T3 (enExample)
DO (1) DOP2016000284A (enExample)
EC (1) ECSP16089579A (enExample)
ES (1) ES2672368T3 (enExample)
HR (1) HRP20180950T1 (enExample)
HU (1) HUE038914T2 (enExample)
IL (2) IL248244B (enExample)
LT (1) LT3134430T (enExample)
MA (2) MA39770A (enExample)
MX (2) MX2016013858A (enExample)
MY (1) MY181986A (enExample)
NO (1) NO2776305T3 (enExample)
PE (1) PE20170299A1 (enExample)
PH (2) PH12020500377A1 (enExample)
PL (1) PL3134430T3 (enExample)
PT (1) PT3134430T (enExample)
RS (1) RS57153B1 (enExample)
RU (1) RU2699285C2 (enExample)
SG (3) SG11201608767XA (enExample)
SI (1) SI3134430T1 (enExample)
SM (1) SMT201800286T1 (enExample)
TR (1) TR201806912T4 (enExample)
TW (2) TWI747178B (enExample)
UA (1) UA118286C2 (enExample)
UY (1) UY36095A (enExample)
WO (1) WO2015164588A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3292143B1 (en) * 2015-05-04 2019-08-21 Apogenix AG Single-chain cd40-receptor agonist proteins
AU2016342420B2 (en) * 2015-10-23 2020-10-01 Apogenix Ag Single-chain LIGHT receptor agonist proteins
CN108430492B (zh) 2015-10-23 2022-05-03 阿珀吉科吉尼科斯股份公司 单链cd27受体激动剂蛋白
JP6959229B2 (ja) * 2015-10-23 2021-11-02 アポジェニックス アーゲー 一本鎖gitr受容体アゴニストタンパク質
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
CA3054286A1 (en) 2016-03-01 2017-09-08 The Board Of Trustees Of The University Of Illinois L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
JP2019518713A (ja) * 2016-03-16 2019-07-04 メリマック ファーマシューティカルズ インコーポレーティッド 癌療法のための改変trail
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CA3027380A1 (en) * 2016-06-13 2017-12-21 Merrimack Pharmaceuticals, Inc. Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
US11578315B2 (en) 2017-08-11 2023-02-14 The Board Of Trustees Of The University Of Illinois Truncated guinea pig L-asparaginase variants and methods of use
WO2019178433A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
WO2019178438A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
EP4149964A2 (en) 2020-05-15 2023-03-22 Apogenix AG Multi-specific immune modulators
CA3217894A1 (en) 2021-05-28 2022-12-01 Gernot Stuhler Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7645700A (en) 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
PT1355942E (pt) 2000-12-07 2008-11-21 Lilly Co Eli Proteínas de fusão de glp-1
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7538088B2 (en) 2002-04-26 2009-05-26 California Institute Of Technology Method for inhibiting angiogenesis by administration of the extracellular domain of D1-1 polypeptide
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
CA2597789A1 (en) 2005-04-15 2006-10-19 Rappaport Family Institute For Research In The Medical Sciences Molecules and methods of using same for treating mcp-1/ccr2 associated diseases
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン,エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
WO2009007120A2 (en) 2007-07-10 2009-01-15 Apogenix Gmbh Tnf superfamily collectin fusion proteins
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2806029B1 (en) * 2008-07-21 2016-05-25 Apogenix AG TNFSF single chain molecules
JP2012502994A (ja) * 2008-09-22 2012-02-02 アムジエン・インコーポレーテツド 治療方法
JP2012504969A (ja) * 2008-10-10 2012-03-01 アナフォア インコーポレイテッド Trail−r1及びtrail−r2に結合するポリペプチド
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
EP2389192A4 (en) * 2009-01-23 2013-01-16 Biogen Idec Inc STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
AU2010334974A1 (en) 2009-12-22 2012-07-12 Novartis Ag Tetravalent CD47-antibody constant region fusion protein for use in therapy
CN102906112B (zh) * 2010-04-13 2016-12-07 米迪缪尼有限公司 Trail r2-特异性多聚体支架
WO2013092983A2 (en) * 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
CN104662039B (zh) 2012-07-18 2019-10-08 阿珀吉尼科斯股份公司 缩短的CD95-Fc变体

Also Published As

Publication number Publication date
MA39770A (fr) 2015-10-29
JP6523331B2 (ja) 2019-05-29
TW202024123A (zh) 2020-07-01
MX2019013587A (es) 2020-01-13
US20210040178A1 (en) 2021-02-11
CR20160516A (es) 2017-05-10
AU2020202247A1 (en) 2020-04-23
RU2016145608A3 (enExample) 2018-12-26
TWI683825B (zh) 2020-02-01
RU2016145608A (ru) 2018-05-28
US20240174731A1 (en) 2024-05-30
JP2019162114A (ja) 2019-09-26
US20180222962A1 (en) 2018-08-09
PE20170299A1 (es) 2017-05-06
KR102079919B1 (ko) 2020-02-24
JP2017513503A (ja) 2017-06-01
EP3134430B1 (en) 2018-03-21
RS57153B1 (sr) 2018-07-31
US20250145688A1 (en) 2025-05-08
SI3134430T1 (en) 2018-05-31
DOP2016000284A (es) 2017-02-15
LT3134430T (lt) 2018-05-10
NZ725476A (en) 2023-09-29
SMT201800286T1 (it) 2018-07-17
AU2018271369A1 (en) 2018-12-20
DK3134430T3 (en) 2018-05-22
PL3134430T3 (pl) 2018-08-31
RU2699285C2 (ru) 2019-09-04
CY1120281T1 (el) 2019-07-10
SG11201608767XA (en) 2016-11-29
EP3366699A1 (en) 2018-08-29
PT3134430T (pt) 2018-04-20
HRP20180950T1 (hr) 2018-08-10
IL248244B (en) 2020-03-31
MX2016013858A (es) 2017-08-02
ECSP16089579A (es) 2018-05-31
US20150337027A1 (en) 2015-11-26
TWI747178B (zh) 2021-11-21
MY181986A (en) 2021-01-18
PH12020500377A1 (en) 2022-11-14
KR20190135546A (ko) 2019-12-06
SG10201806465TA (en) 2018-08-30
AU2015249649B2 (en) 2018-10-04
BR112016024515A2 (pt) 2017-10-10
JP6714751B2 (ja) 2020-06-24
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
ES2672368T3 (es) 2018-06-14
CA2946402C (en) 2023-02-28
AU2015249649A1 (en) 2016-11-10
EP3134430A1 (en) 2017-03-01
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
CA2946402A1 (en) 2015-10-29
IL248244A0 (en) 2016-11-30
UY36095A (es) 2015-10-30
PH12016502079A1 (en) 2016-12-19
IL272612A (en) 2020-03-31
MA45069A (fr) 2019-04-03
KR20170012257A (ko) 2017-02-02
UA118286C2 (uk) 2018-12-26
NO2776305T3 (enExample) 2018-01-27
US9908927B2 (en) 2018-03-06
AR100168A1 (es) 2016-09-14
WO2015164588A1 (en) 2015-10-29
PH12016502079B1 (en) 2016-12-19
CN106459221B (zh) 2020-09-01
BR112016024515B1 (pt) 2020-03-31
HUE038914T2 (hu) 2018-12-28
TW201620928A (zh) 2016-06-16
SG10202111785VA (en) 2021-12-30
CL2016002683A1 (es) 2017-07-07

Similar Documents

Publication Publication Date Title
US20240174731A1 (en) Single-chain trail-receptor agonist proteins
US10683332B2 (en) Single-chain light receptor agonist proteins
WO2017068183A1 (en) Single-chain cd137-receptor agonist proteins
US10683338B2 (en) Single-chain TL1A receptor agonist proteins
WO2017068185A1 (en) Single-chain gitr-receptor agonist proteins
WO2017068181A1 (en) Single-chain ox40-receptor agonist proteins
HK1260151A1 (en) Single-chain trail-receptor agonist proteins
HK1235072B (en) Single-chain trail-receptor agonist proteins
HK1235072A1 (en) Single-chain trail-receptor agonist proteins
NZ725476B2 (en) Single-chain trail-receptor agonist proteins